Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279786 · ClinicalTrials.gov registry record
B2-Adrenergic Receptor Polymorphisms
A clinical trial of Status Asthmaticus, sponsored by Connecticut Children's Medical Center.
- Completed
- Registry status
- 126
- Enrollment target
- 1
- Study location
NCT00279786: Completed study of Status Asthmaticus, sponsored by Connecticut Children's Medical Center.
NCT00279786 is a study of Status Asthmaticus that has completed, run by Connecticut Children's Medical Center. The registered enrollment target is 126 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00279786, a study of Status Asthmaticus, has completed, sponsored by Connecticut Children's Medical Center.
- COMPLETED
- Registry status
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
Beta(2)-adrenergic receptor (BAR) agonists are the most important group of drugs used in the treatment of asthma. In children unresponsive to inhaled BAR agonist therapy, higher dose systemic BAR agonist therapy is frequently the next step in treatment. Despite the widespread use of intravenous BAR agonist therapy for pediatric status asthmaticus, there is controversy regarding the efficacy of this therapy. A number of studies have established that genetic variations of the BAR have important effects in modulating responses to BAR agonist therapy for asthma. In particular, changes in amino acid position 16 of the BAR gene are thought to be the most functionally important. Patients encoded for two glycine amino acids, rather than arginine, at this position appear to have more severe asthma and to respond differently to acute BAR agonist therapy. Our hypothesis is that genotypic differences may contribute to poor response to acute BAR agonist treatment. We propose to conduct a prospective observational study to determine the influence of a patient's BAR genotype on the response to acute BAR agonist therapy. Our specific hypothesis is that children with genetic polymorphisms of the gene encoding the BAR will have a decreased response to acute high-dose continuous BAR therapy (both inhaled and intravenous) compared to other children. Our primary outcome is ICU length of stay. Secondary outcomes are 1. to assess the rate of improvement in clinical asthma score based on genotype, and 2. to attempt to correlate asthma phenotype with genotype by comparing demographic data and hospital course.
Conditions Studied
Interventions
- PROCEDURE Blood draw
Study Locations (1)
Connecticut
- CT Children's Medical Center - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-01 |
What the finished NCT00279786 record still lists
NCT00279786 is an observational study that tracks outcomes without assigning an intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Status Asthmaticus appearing as the primary indexed condition, and to 1 intervention - of which Blood draw is the first listed.
NCT00279786 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT00279786 about?
NCT00279786 is a clinical study titled "B2-Adrenergic Receptor Polymorphisms". Beta(2)-adrenergic receptor (BAR) agonists are the most important group of drugs used in the treatment of asthma. In children unresponsive to inhaled BAR agonist therapy, higher dose systemic BAR agonist therapy is frequently the next step in treatment. Despite the widespread use of intravenous BAR ...
What is the current status of trial NCT00279786?
This trial is currently completed. The enrollment target is 126 participants. The study started on 2005-12. Estimated completion is 2009-01.
What conditions does trial NCT00279786 study?
This clinical trial studies the following conditions: Status Asthmaticus.
What interventions are being tested in trial NCT00279786?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT00279786?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00279786 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Status Asthmaticus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia